Literature DB >> 17495482

Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions.

Stéphanie Sauvageau1, Eric Thorin, Alexandre Caron, Jocelyn Dupuis.   

Abstract

BACKGROUND: Roles of endothelin (ET) receptors (R) and of the endothelium on ET-1-induced pulmonary vasoreactivity are subjects of debate. This stems from endothelial ET(B)-R that can release both vasodilators and vasoconstrictors. The aim of this study was to evaluate the roles of the endothelium and of ET-Rs on ET-1-induced pulmonary vasoreactivity.
METHODS: Pharmacological experiments were performed in isolated rat lungs and in pulmonary resistance arteries.
RESULTS: In isolated lungs, ET-1 and the selective ET(B)-R agonist sarafotoxin 6c (S6c) induced a similar vasoconstriction. ET-1 constriction was reduced by a selective ET(A)-R antagonist; however, the selective ET(B)-R antagonist had no significant effect. In preconstricted lungs, ET(B)-R stimulation caused mild vasodilation at low concentrations but severe vasoconstriction at higher concentrations. In isolated arteries, responses to ET-1 and S6c were not different and unaffected by removal of endothelium. Interestingly, concentrations of ET(A)-R and ET(B)-R antagonists that only mildly reduced ET-1 vasoconstriction when used alone, prevented maximal constriction and greatly reduced vascular sensitivity to ET-1 when used in combination.
CONCLUSION: In rat lungs, both ET(A)-R and ET(B)-R contribute to ET-1-induced pulmonary vasoconstriction with evidence of interaction between receptors. A mild vasodilator role of the endothelial ET(B)-R is evident only at low agonist concentration and when baseline vascular tone is increased. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495482     DOI: 10.1159/000102534

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  17 in total

Review 1.  Endothelin receptors: what's new and what do we need to know?

Authors:  Stephanie W Watts
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

Review 2.  Working under pressure: coronary arteries and the endothelin system.

Authors:  Albert Nguyen; Nathalie Thorin-Trescases; Eric Thorin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-17       Impact factor: 3.619

Review 3.  The cardiovascular physiology and pharmacology of endothelin-1.

Authors:  Eric Thorin; Martine Clozel
Journal:  Adv Pharmacol       Date:  2010

4.  Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Emily Brantley; Seok Joong Yun; Junqin He; Marva Maya; Fahao Zhang; Qiuyu Wu; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

5.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

6.  Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.

Authors:  Olga Rafikova; Ruslan Rafikov; Sanjiv Kumar; Shruti Sharma; Saurabh Aggarwal; Frank Schneider; Danny Jonigk; Stephen M Black; Stevan P Tofovic
Journal:  Free Radic Biol Med       Date:  2012-11-29       Impact factor: 7.376

7.  Reactive oxygen species mediate RhoA/Rho kinase-induced Ca2+ sensitization in pulmonary vascular smooth muscle following chronic hypoxia.

Authors:  Nikki L Jernigan; Benjimen R Walker; Thomas C Resta
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

8.  Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.

Authors:  Stéphanie Sauvageau; Eric Thorin; Louis Villeneuve; Jocelyn Dupuis
Journal:  Pulm Pharmacol Ther       Date:  2009-08       Impact factor: 3.410

9.  Conceptual approaches for treatment of phosgene inhalation-induced lung injury.

Authors:  Wesley W Holmes; Brian M Keyser; Danielle C Paradiso; Radharaman Ray; Devon K Andres; Betty J Benton; Cristin C Rothwell; Heidi M Hoard-Fruchey; James F Dillman; Alfred M Sciuto; Dana R Anderson
Journal:  Toxicol Lett       Date:  2015-11-10       Impact factor: 4.372

10.  Endothelin-3-dependent pulmonary vasoconstriction in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Stéphanie Sauvageau; Eric Thorin; Louis Villeneuve; Jocelyn Dupuis
Journal:  Peptides       Date:  2008-08-15       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.